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Here we present new and original data on the endogenous conversion of tyrosol (Tyr) into hydroxytyrosol (OHTyr) in humans
and its effects on the cardiovascular system. A randomized,
crossover, controlled clinical trial was performed with individuals
at cardiovascular risk (n ¼ 33). They received white wine (WW)
(females 1, males 2 standard drinks/day), WW plus Tyr capsules
(WW þ Tyr) (25mg Tyr capsule, one per WW drink), and water
(control) ad libitum. Intervention periods were of 4 weeks preceded by three-week wash-out periods. We assessed the conversion of Tyr to OHTyr, its interaction with a polygenic activity score
(PAS) from CYP2A6 and CYP2D6 genotypes, and the effects on
cardiovascular risk markers. For further details and experimental
ﬁndings please refer to the article “Cardiovascular beneﬁts of
tyrosol and its endogenous conversion into hydroxytyrosol in
humans. A randomized, controlled trial” [1].
© 2019 The Author(s). Published by Elsevier Inc. This is an open
access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).
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Speciﬁcations Table
Subject
Speciﬁc subject area
Type of data
How data were acquired

Data format
Parameters for data collection

Description of data collection
Data source location
Data accessibility
Related research article

Nutrition
Nutritional biochemistry and genotype interaction
Tables, Figures, File text
HPLC-MS-MS for Tyr and OHTyr
Genotyping of allelic variants of CYP2A6 and CYP2D6 .A polygenic score activity was
calculated
Reactive hyperemia index, RHI for endothelial function
Automated methods, HPLC, and ELISA for cardiovascular risk biomarkers
Real-time polymerase chain reaction (PCR) for gene expression
Raw data collection and analysis
Before and after each one of the three interventions with 1) white wine (WW) (females 1,
males 2 standard drinks/day), 2) WW plus Tyr capsules (WW þ Tyr) (25mg Tyr capsule, one
per WW drink), and 3) water (control) ad libitum. Intervention periods were of 4 weeks
preceded by 3-weeks washout periods.
Biological samples were collected and processed in the context of a randomized controlled
intervention trial by ﬁeld investigators
Barcelona, Spain
With the article
Boronat A et al. Cardiovascular beneﬁts of tyrosol and its endogenous conversion into
hydroxytyrosol in humans. A randomized, controlled trial. Free Radical Biol Med, 2019 Aug
31;143:471-481. https://doi.org/10.1016/j.freeradbiomed.2019.08.032.

Value of the Data
 The presented data provide further details on how the polygenic activity score to evaluate the efﬁciency of Tyr to OHTyr
conversion was generated.
 This report describes the effects on cardiovascular biomarkers of an intervention with white wine and white wine
enriched with Tyr.
 They are useful to predict the effects of nutritional interventions rich in Tyr (olive oil, wine, beer …) considering the
interaction with individual's genetic background.
 The present data are of interest for the effects of Tyr alone and in the future within Tyr rich foods
 These data can be used for the design of new nutraceutical based on Tyr ingestion in humans
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1. Data
Thirty-three participants (21 men and 12 women) were randomly allocated to participate in a
clinical trial, and 32 participants completed the trial. Initially, 192 subjects were assessed for eligibility,
157 were excluded for 1) not meeting the inclusion criteria, 2) refusing to participate, 3) taking
medication non compatible with the interventions, 4) suffering from a coronary heart disease, 5)
having undergone bariatric surgery, 6) intestinal alterations, 7) mobility problems, 8) chronic inﬂammatory diseases, 9) dysregulated hypertension, 10) illicit drug consumption, 11) heavy alcohol
consumption, and 12) hepatic alterations. The 33 volunteers were randomly allocated to receive the
following treatments for 4 weeks: WW, WW þ Tyr and control intervention [1] (Fig. 1).
Baseline characteristics of the participants are shown in Table 1. No dietary differences were
observed among interventions (Table 2). Volunteers were genotyped for multiple allelic variants of
CYP2A6 and CYP2D6 (Table 3). For each enzyme, an activity score was given to each volunteer according
to the alleles identiﬁed (Table 4). A pooled polygenic activity score (PAS) was calculated by adding the
two activity scores together.
On the basis of PAS, 11 individuals were categorized as low (LA, PAS range: 1e2.5), 19 as normal (NA,
PAS range: 3e4), and 2 as rapid (RA, PAS range ¼ 5) activity metabolizers. Due to their low number, RAs
were excluded for analyses. Age and gender were equally distributed among the three groups. The
conversion of Tyr into OHTyr was assessed by measuring OHTyr and Tyr urinary recovery following
each treatment. No changes were observed in lipid biomarkers (Table 5) with exception of HDLcholesterol (HDLc) which increased after WW and WW þ Tyr. HDL-c increased in a dose-dependent
manner with the content of alcohol plus Tyr administered in all participants (p ¼ 0.027 for linear
trend), among men (p ¼ 0.001 for linear trend), and with a borderline signiﬁcance in the NA group
(p ¼ 0.082) (Fig. 2). Endothelin-1 levels at the end of WW þ Tyr were lower than at the end of WW
intervention (Table 6). Table 7 outlines the transcriptomic changes observed in genes related with
endothelial function. Changes are grouped by sex and PAS. Fig. 3 compares the effects observed in WW
and WW þ Tyr intervention.

Fig. 1. Schema of the clinical trial. Intervention periods of 4 weeks. WO: wash-out period (3 weeks) without alcohol and following a
low-phenolic content diet. WW (white wine): 2 glasses (270 mL, 27 g of alcohol, 2.8 mg of Tyr and 0.4 mg of OHTyr) for men, and 1
glass (135 mL, 13.5 mg, 1.4 mg of Tyr, and 0.2 mg of OHTyr) for women. WW þ Tyr (white wine plus tyrosol): 2 glasses of wine: 270
mL, 27 g of alcohol, 2.8 þ 50 mg of Tyr (2 capsules), and 0.4 mg of OHTyr for men, and 1 glass:135 mL, 13.5 g of alcohol, 1.4 mg þ 25
mg of Tyr (1 capsule), and 0.2 mg of OHTyr for women.
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Table 1
Baseline characteristics of the participants.
Variable

Values

Age, y
Gender, n (%)
Women
Men
BMI, kg/m2
LDL cholesterol, mg/dL
HDL cholesterol, mg/dL
Total cholesterol, mg/dL
Triglycerides, mg/dL
Cardiovascular Risk factors, n (%)
Current smokers
Family history of premature CHD
Obesity (BMI  25kg/m2)
Type 2 Diabetes
Hypertension
High LDL cholesterol (>130 mg/dL)
Low HDL cholesterol (<40 mg/dL for men or <50 mg/dL for women)
Medications, n (%)
Alfa blockers
Beta blockers
ACE inhibitors
Angiotensin II receptor antagonists
Diuretics
Statins
Oral hypoglycemic drugs
Acetylsalicylic acid

65.3 ± 6.2
12 (36.4%)
21 (63.6%)
32.6 ± 4.2
118 ± 34.4
50.2 ± 12.9
192 ± 39.3
120 ± 72.2
6 (18.2%)
6 (19.4%)
32 (97.0%)
13 (39.4%)
28 (84.8%)
25 (75.6%)
8 (24.2%)
2 (6.1%)
6 (18.2%)
14 (42.4%)
11 (33.3%)
13 (39.4%)
16 (48.5%)
12 (36.4%)
10 (30.3%)

Data presented as mean ± SD or n (%) (n ¼ 33). BMI, body mass index; LDL, low density lipoproteins; HDL, high
density lipoproteins; CHD, coronary heart disease.

2. Experimental design, materials, and methods
2.1. Study design
A randomized, controlled, clinical trial with 33 individuals at cardiovascular risk (21 men and 12
women) was performed (Fig. 1). Inclusion criteria were to be at high risk for coronary heart disease
(CHD) with 3 or more risk factors including: current smoking (>1 cig/day during the last month),
hypertension (140/90 mmHg or antihypertensive medication), high LDL cholesterol (>130 mg/dl or
lipid-lowering therapy), low HDL-cholesterol (40 mg/dl in men and 50 mg/dl in women), overweight/obesity (body mass index 25 kg/m2), a family history of premature CHD, and/or type II diabetes treated with oral hypoglycemic agents; and to have a social or recreational use of ethanol/wine
consumption at least once during lifetime. Exclusion criteria were participants with a history of cardiovascular disease or severe chronic illness, chronic inﬂammatory diseases, BMI > 40 kg/m2, suffered
from any severe illness or undergone major surgery in the last three months prior to the clinical trial, an
alcohol consumption exceeding 8 units or 80 g per day, a history of alcohol hypersensitivity/intolerance, illicit drug consumption, intake of antioxidant supplement(s), the taking of sedative drugs that
could potentially interact with alcohol, multiple allergies or intestinal diseases, being vegetarian of
following special diets, a history of food allergies or intolerances, illiteracy, and any condition that
limited mobility making trial visits impossible or worsening adherence to treatments.
Participants were asked to follow a controlled diet with a moderate content of antioxidants and to
abstain of any alcoholic drinks (except in the framework of treatment allocations) thorough the trial.
The consumption of certain food was limited to a maximum of 1) vegetables (including pulses): one
serving/day, 2) fruits (or juices): 2 pieces/day, 3) ordinary olive oil: maximum 25 mL/day, 4) drinks
containing xanthines (coffee, tea, cola, energy drinks …): maximum 3 cups/day, 5) chocolate:
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Table 2
Energy, nutrients, and ﬁber at the beginning and at the end of the clinical trial.
Variable

Treatment
Control

Energy, kcal/day
Baseline
1695 ± 446
12-week
1643 ± 361
HC, % energy
Baseline
38.2 ± 8.6
12-week
38.3 ± 7.3
HC, grams
Baseline
159 ± 48
12-week
156 ± 41
Protein, % energy
Baseline
20.9 ± 4.0
12-week
21.2 ± 4.1
Protein, grams
Baseline
88 ± 25
12-week
87 ± 25
Total Fat, % energy
Baseline
40.7 ± 7.5
12-week
40.2 ± 7.2
Total Fat, grams
Baseline
78 ± 29
12-week
74 ± 23
SFA, % energy
Baseline
11.4± 3.8
12-week
10.7 ± 3.7
SFA, grams
Baseline
22 ± 12
12-week
20 ± 10
MUFA,% energy
Baseline
19.8 ± 5.0
12-week
20.1 ± 4.2
MUFA, grams
Baseline
53.3 ± 21.0
12-week
51.9 ± 21.2
PUFA, % energy
Baseline
6.1 ± 2.6
12-week
5.9 ± 2.3
PUFA, grams
Baseline
12 ± 6
12-week
11 ± 7
Fiber, g/day
Baseline
20 ± 7
12-week
20 ± 8

P*
P

WW

P

WWþTYR

P

0.616

1663 ± 421
1650 ± 354

0.868

1624 ± 370
1737 ± 450

0.082

0.906

40.2 ± 6.4
37.6 ± 7.7

0.095

38.8 ± 6.3
37.8 ± 7.5

0.360

0.811

165± 43
153 ± 40

0.209

157 ± 38
163 ± 45

0.532

0.578

19.2 ± 3.0
19.5 ± 4.8

0.028

21.5 ± 4.5
19.0± 3.9

0.142

0.939

79 ± 19
81 ± 30

0.651

86 ± 24
82 ± 23

0.184

0.625

40.3 ± 6.2
36.7 ± 9.0

0.496

39.2 ± 6.6
38.6 ± 6.3

0.230

0.489

76 ± 28
68 ± 24

0.015

72 ± 24
76± 28

0.809

0.526

10.1 ± 3.0
10.1 ± 3.9

0.953

11.4 ± 4.2
10.4 ± 3.7

0.272

0.428

19 ± 9
19 ± 10

0.873

21 ± 12
21 ± 11

0.855

0.893

19.7 ± 4.2
18.4 ± 5.1

0.177

18.6 ± 5.0
19.6 ± 3.5

0.172

0.475

53.8 ± 15.5
46.5 ± 13.3

0.274

53.0 ± 16.6
50.0 ± 14.3

0.054

0.697

6.8 ± 2.5
5.2 ± 2.1

0.222

6.0 ± 2.1
5.4 ± 1.9

0.179

0.901

13 ± 8
10 ± 5

0.025

11 ± 4
11 ± 6

0.960

0.894

23 ± 11
23 ± 11

0.848

20 ± 8
21 ± 9

0.408

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

Dietary data is expressed as mean ± SD (N ¼ 32). HC, carbohydrates; SFA, saturated fatty acids; MUFA, monounsaturated fatty
acids; PUFA, polyunsaturated fatty acids. P Intra-treatment comparisons by Student's t-test. *P value for ANOVA repeated
measures adjusted by age and sex.

maximum one piece (small 15 gr)/day, 6) nuts: maximum 30 g (a small handful)/week, and 7) ﬁsh:
maximum 3 times per week (150 g/serving).
During the control intervention participants were allowed to only drink water (no alcohol. wine or
supplemented Tyr or OHTyr). The reason for different WW doses for men and women was in order to
follow the American Heart Association (AHA) guidelines, which limit alcohol consumption to one drink
in women and two in men, preferably taken at meals [2]. The doses of wine administered are within
those recommended by the AHA.
A 24 h food recall was performed to assess dietary intake before and after each intervention period.
Physical activity was recorded at the beginning and end of the clinical trial and assessed by the
Minnesota Leisure Time Physical Activity Questionnaire, validated for the Spanish population [3].
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Table 3
Characteristics of CYP2A6 and CYP2D6 SNPs tested.
Tested Allelic Variants

Reference Number

Nucleotide Substitution

Amino acid substitution

TaqMan Assay ID

CYP2A6

rs1801272
rs28399433
rs1135840
rs16947
rs3892097
rs5030656
rs1065852
rs769258
rs28371725

479T > A
- 48T > G
4181G > C
2851C > T
1847G > A
2616_2618delAAG
100C > T
31G > A
2989G > A

Leu160His
Upstream
Ser486Thr
Arg296Cys
Intron Variant
Lys281del
Pro34Ser
Val11Met
Intron Variant

C_27861808_60
C_30634332_10
C_27102414_10
C_27102425_10
C_27102431_DO
C_32407229_60
C_11484460_40
C_27102444_80
C_34816116_20

CYP2D6

Table 4
Activity score assigned to each tested variant in the PAS model.
Tested Allelic

Variants

Functional consequence

Activity score

Deﬁning SNP

CYP2A6

*2
*4
*9
*12
*1xN
*2

No function
No expression
Decreased
Decreased
Increased
Normal

0
0
þ0.5
þ0.5
þ2
þ1

*4
*5
*9
*10

No function
No expression
Decreased
Decreased

0
0
þ0.5
þ0.5

*35

Normal

þ1

*41

Decreased

þ0.5

*1xN
*2xN
*35xN

Increased

þ2

479T > A
Gene deletion
- 48T > G
Hybrid allele with CYP2A7
Multiple copies
2851C > T
4181 G > C
1847 G > Aa
Gene deletion
2616 del AGG
100C > T
4181 G > C
31G > A
2851C > T
4181 G > C
2989 G > A
2851C > T
4181 G > C
Multiple copies

CYP2D6

a

*4 sub-alleles can commonly present other SNPs such as 100C > T, 4181 G > C and/or 2851C > T.

Table 5
Changes in lipid and inﬂammatory biomarkers (mg/dL).
Interventions
Control

Total Cholesterol
LDL cholesterol
Triglycerides
Glucose
hsCRP

1.8 ± 12.5
1.0 ± 14.1
14.7 ± 62.0
0.9 ± 13.4
0.2 ± 1.3

WW

2.9 ± 21.8
0.1 ± 17.8
6.0 ± 25.9
2.7 ± 10.3
0.02 ± 0.3

WW þ TYR

7.7 ± 24.4
4.7 ± 22.3
0.9 ± 25.7
2.6 ± 12.0
0.01 ± 0.2

P value for WW þ Tyr
vs Control

vs WW

0.665
0.511
0.290
0.849
0.443

0.753
0.761
0.788
0.999
0.516

Changes expressed as mean ± SD (N ¼ 32). LDL, low density lipoprotein; hsCRP, high sensitivity C reactive protein. ANOVA
adjusted by age, sex and smoking habits, LDL cholesterol at the beginning of the clinical trial, and baseline levels.

A general physical examination, and routine urine, blood chemical and hematological analyses, were
performed at the beginning and end of the trial. Blood and 24h-urine samples were collected at fasting
state before and after each intervention period. Blood was collected into 10 mL tubes containing EDTA
and centrifuged (1700g, 15 min, 4  C), and plasma and buffy coat samples were then isolated. Peripheral blood mononuclear cells (PBMC) were isolated using a Vacutainer Cell Preparation Tube

A. Boronat et al. / Data in brief 27 (2019) 104787
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Fig. 2. Changes in HDL cholesterol (HDL-c) after interventions. Change in HDL-c compared to the baseline of the intervention
expressed as mean and SD in all participants (A), only men (B) and only normal activity metabolizers (C). ANOVA adjusted by age, sex
and smoking habits, LDL cholesterol at the beginning of the clinical trial, and baseline levels * P < 0,05; **P < 0,01.
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Table 6
Endothelin concentrations (ng/dL) after interventions.
Interventions

All participants
Women
Men
Genotype interaction
LA
NA

Control

WW

WW þ TYR

P value for WW þ Tyr
vs Control

vs WW

2.15 ± 0.90
2.38 ± 1.07
2.01 ± 0.80

2.33 ± 1.07
2.57 ± 1.11
2.16 ± 1.08

2.03 ± 0.82
2.12 ± 0.81
1.99 ± 0.87

0.572
0.479
0.990

0.031
0.108
0.463

1.93 ± 0.69
2.24 ± 0.95

2.25 ± 0.96
2.48 ± 1.32

1.89 ± 0.72
2.13 ± 1.07

0.981
0.747

0.203
0.068

Endothelin-1 concentrations are expressed as mean ± SD (N ¼ 32). WW, white wine; WW þ Tyr, white wine plus tyrosol (Tyr)
capsules; LA, low activity group metabolizers; NA, normal activity group metabolizers. ANOVA adjusted by age, sex, smoking,
acetylsalicylic acid consumption, and baseline levels. *P < 0.05 versus its baseline; P value, signiﬁcance for inter-intervention
comparisons.

(CPT™) and kept for RNA extraction. Plasma, urine, and PBMC samples were frozen at 80  C until
analysis. Genomic DNA isolation from buffy coat was performed with QIAamp DNA Blood Midi Kit
(Qiagen, Dusseldorf, Germany).
2.2. Tyr and OHTyr metabolites analysis
The urinary concentrations of Tyr and OHTyr metabolites were determined from samples collected
before and after each intervention following a validated methodology [4]. Brieﬂy, 0.5 mL of urine was
diluted with 0.5 mL of puriﬁed water, spiked with 10 mL of internal standard mixture (containing 10
mg/mL of 3-(4-hydroxyphenyl)-1-propanol, 3-(4-hydroxyphenyl)-1-propanol glucuronide and 10 mg/
mL HT-10 -O-sulfate) and stabilized with 1 mL of phosphoric acid 4%. Thereafter, samples went under a
solid-phase extraction using Oasis HLB columns 3 mL, 60-mg cartridges from Waters Corporation
(Milford, MA USA). First, samples were loaded into cartridges then washed with 2 mL of puriﬁed water.
Thereafter, the compounds of interest were eluted from the cartridge with 2 mL of pure methanol. The
methanol extracts were then evaporated until dryness under a stream of nitrogen (29  C, 10e15 psi).
Finally, the dried extracts were reconstituted with a mixture of mobile phases (95% A and 5% B v/v),
transferred into HPLC microvials, and analyzed using LC-MS/MS. To prepare blank samples and calibration curves, urine from volunteers after consuming a diet poor in Tyr and OHTyr- Tyr and OHTyr
metabolite concentrations were below quantiﬁcation limits in these blank samples. Blank urine was
spiked with increasing concentrations of the metabolites of interest, and then processed in the same
manner as samples (described above). Identiﬁcation and quantiﬁcation of the metabolites was performed using an Agilent 1200 series HPLC system coupled to a triple quadrupole (6410 Triple Quad
LC/MS) mass spectrometer with an electrospray interface from Agilent Technologies (Santa Clara, CA,
USA). For the chromatographic separation, an Acquity UPLC®BEH C18 column (100 mm  3.0 mm i.d.,
1.7 mm particle size) from Waters Corporation (Milford, MA, USA) was used at 40  C. The composition of
mobile phase A was 0.01% (v/v) formic acid in water, and mobile phase B was acetonitrile with 0.01%
(v/v) of formic acid. Injection volume was 10 mL and the ﬂow rate was set at 0.25 mL/min. The ion
source operated in negative ionization for 27 minutes. Finally, urinary concentrations of each
metabolite were standardized with the total urinary excretion volume to obtain the total recovery of
each metabolite. Quantiﬁed Tyr metabolites included Tyr -4-sulfate and Tyr -4-glucuronide. OHTyr
metabolites quantiﬁed were OHTyr -3-sulfate, OHTyr-4-sulfate, OHTyr-acetate-3-sulfate, OHTyr-3glucuronide, OHTyr-4-glucuronide, and homovanillyl alcohol (HVAL)-4-glucuronide. Total Tyr and
total OHTyr correspond to the molar sum of their respective quantiﬁed metabolites.
2.3. Genotyping
Volunteers were genotyped for multiple allelic variants of CYP2A6 and CYP2D6 using TaqMan
genotyping assays (Applied Biosystems, Foster City, CA, USA) SNP genotyping was performed with a
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Table 7
Transcriptomic changes (% change versus baseline) after interventions.
Intervention
Control

CD40L
All participants
Women
Men
Genotype interaction
LA
NA
P65/RElA
All participants
Women
Men
Genotype interaction
LA
NA
CFH
All participants
Women
Men
Genotype interaction
LA
NA
iNOS
All participants
Women
Men
Genotype interaction
LA
NA
eNOS
All participants
Women
Men
Genotype interaction
LA
NA
VEGFA
All participants
Women
Men
Genotype interaction
LA
NA

WW

WW þ Tyr

P value for WW þ Tyr
vs Control

vs WW

8.9 ± 60.6
10.7 ± 75.4
24.6 ± 47.2

21.7 ± 62.3
28.8 ± 59.5
20.4 ± 66.2

26.8 ± 34.2y
29.9 ± 33.7*
25.5 ± 35.8*

0.042
0.743
0.016

0.003
0.063
0.024

4.8 ± 66.7
20.1 ± 60.0

11.1 ± 59.8
16.7. ± 56.5

17.1 ± 35.6
28.2 ± 33.9y

0.874
0.011

0.514
0.020

1.1 ± 0.5
7.6 ± 54.0
22.9 ± 41.9

1.18 ± 0.5
26.9 ± 63.3
13.4 ± 48.2

0.9 ± 0.30
16.9 ± 29.8
2.2 ± 28.6

0.229
0.896
0.157

0.048
0.089
0.484

16.7 ± 63.5
6.7 ± 41.1

6.3 ± 45.3
22.5 ± 58.3

3.0 ± 43.4
-.12,5 ± 20.9

0.584
0.414

0.886
0.054

19.8 ± 57.6
9.2 ± 57.5
27.9 ± 59.5

28.8 ± 56.5*
48.4 ± 51.9*
16.6 ± 58.9

9.1 ± 51.5
11.9 ± 63.2
18.1 ± 40.9*

0.115
0.994
0.013

0.025
0.334
0.048

21.4 ± 77.7
22.4 ± 46.9

35.2 ± 74.8
22.6 ± 45.1

16.7 ± 29.5
0.0 ± 62.8

0.359
0.438

0.150
0.433

5.0 ± 38.3
16.9 ± 28.8
2.7 ± 41.2

36.7 ± 82.6*
56.1 ± 109.4
29.9 ± 71.3

19.7 ± 62.4
2.3 ± 24.1
27.5 ± 70.4

0.734
0.897
0.470

0.007
0.303
0.019

6.3 ± 36.2
4.7 ± 38.1

17.0 ± 66.9
46.2 ± 26.7

33.0 ± 52.4
10.4 ± 69.6

0.299
0.996

0.091
0.080

11.7 ± 65.6
13.2 ± 71.7
12.9 ± 65.5

34.9 ± 72.2*
42.2 ± 42.1*
26.4 ± 83.7

8.2 ± 50.2
14.7 ± 48.8
20.5 ± 49.4

0.509
0.997
0.351

0.035
0.565
0.115

4.8 ± 54.9
28.3 ± 72.9

28.9 ± 77.8
34.8 ± 74.6

16.2 ± 62.6
0.2 ± 44.8

0.910
0.536

0.344
0.334

14.3 ± 58.1
12.6 ± 59.0
9.4 ± 55.4

32.2 ± 69.7*
30.4 ± 68.9
26.2 ± 67.9

6.2 ± 45.2
3.0 ± 61.6
10.0 ± 36.3*

0.398
0.533
0.870

0.045
0.112
0.500

26.3 ± 65.9
7,7 ± 57.6

19.4 ± 75.6
27.7 ± 60.1

3.0 ± 40.6
1.1 ± 46.5

0.497
0.896

0.665
0.256

Changes are expressed as mean ± SD (N ¼ 32). WW, white wine; WW þ Tyr, white wine plus tyrosol (Tyr) capsules; LA, low
activity group metabolizers; NA, normal activity group metabolizers. CD40L, CD40 ligand; CFH, complement factor H; eNOS,
endothelial nitric oxide synthase 3; iNOS, inducible nitric oxide synthase; p65/RELA, transcription factor p65 (RELA); VEGFA,
vascular endothelial growth factor. ANOVA adjusted by age and sex. *P < 0.05, yP < 0.001 versus its baseline; P value, signiﬁcance
for inter-intervention comparisons.

TaqMan allelic discrimination system (Applied Biosystems, Foster City, CA, USA). Copy-number variations (CYP2A6 *4, *12, and CYP2D6 *5, and duplications) were analyzed with speciﬁc copy number
assays. When these allelic variants were not detected, a designation of *1 (e.g. wildtype) was assigned.
2.3.1. SNP genotyping
Table 3 shows the characteristics of CYP2A6 and CYP2D6 tested allelic variants. The following SNPs
were analyzed: for CYP2A6 *2 and *9, and for CYP2D6 *2, *4, *9, *10, *35, and *41. TaqMan SNP genotyping assay were used, which included FAM™ and VIC™ dye-labeled TaqMan pre-designed proves
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Fig. 3. Comparison of the effects of white wine (WW) (blue) versus those of white wine plus tyrosol (WW þ Tyr) (Green), CD40L,
CD40 ligand; NF-KB, nuclear factor kappa B; CFH, complement factor H; iNOS, inducible nitric oxide synthase; eNOS, endothelial
nitric oxide synthase.

speciﬁcs for each SNP. PCR was performed in a QuantStudio™ 12K Flex Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). Reactions were prepared with 10 ng of DNA, 0.25 mL of TaqMan SNP
Genotyping Assay, and 2.5 mL of TaqMan Genotyping Master Mix (Applied Biosystems, Foster City, CA,
USA). SNP determination was made using allelic discrimination plots with TaqMan Genotyper Software
(Applied Biosystems, Foster City, CA, USA).
2.4. Copy number variation (CNV) detection analysis
TaqMan CNV assays were used to analyze CYP2A6 allelic variants *4, *12 (Hs07545274_cn;
Hs07545275_cn), and CYP2D6 allelic variants *5 (deletion),*1xN, *2xN, and *35xN (Hs00010001_cn).
Real time qPCR was performed using the speciﬁc TaqMan assays. Quantitative PCR was performed in
QuantStudio™ 12K Flex Real-Time PCR System (Applied Biosystems, Foster City, USA). Reaction was
carried in 384-well plates with a mixture of TaqMan Master Mix (Applied Biosystems, Foster City, CA,
USA), CNV assays, 10 ng DNA/well and RNase P as reference (Applied Biosystems, Foster City, CA, USA).
Reactions were performed in duplicates. Copy number calls were made with the Expression Suite
Software v1.0.3 (Applied Biosystems, Foster City, CA USA). CYP2D6 gene duplications as previously
described [5]. First, a speciﬁc 6.6 kb long piece of CYP2D6 was ampliﬁed. Second, a 3.5 kb fragment was
ampliﬁed from alleles carrying gene duplications. Every duplication-positive sample was further
analyzed using two long-range PCR reactions that allow to discriminate among CYP2D6*1xN, *2xN, and
*4xN duplications to determine allele-deﬁning SNPs.
2.5. Polygenic activity score
Tested allelic variants were categorized into: those with no-function (CYP2A6 *2, *4; CYP2D6 *4,*5);
decreased function (CYP2A6 *9,*12; CYP2D6 *9,*10,*11); normal function (CYP2A6 *1; CYP2D6 *1,*2,*35);
and increased function (CYP2A6 *1xN; CYP2D6 *1xN,*2xN,*35xN). A score of 0, 0.5, 1 or 2 was assigned
for the presence of each allele (Table 4). For each enzyme, an activity score was given to each volunteer
according to the identiﬁed alleles and classiﬁed as detailed above based on the method described by
Gaedigk et al. [6]. A pooled polygenic activity score (PAS) was calculated by adding together the activity
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scores of both enzymes. Finally, according to their PAS, individuals were placed into three groups of
predicted activity: low (LA), normal (NA), and rapid activity (RA) groups.
2.6. Endothelial function measurement
Endothelial function was assessed before and after interventions by monitoring endotheliummediated changes (reactive hyperemia index, RHI) in the digital pulse waveform, known as the Peripheral Arterial Tone (PAT) signal (EndoPAT 2000; Itamar Medical Inc., Caesarea, Israel). Specially
designed ﬁnger probes were placed on the middle ﬁnger of each subject's dominant hand. The probes
comprised a system of inﬂatable latex air cuffs connected by pneumatic tubes to an inﬂating device
controlled through a computer algorithm. A constant counter pressure (pre-determined by baseline
DBP) was applied through the air cushions. Pulsatile volume changes of the distal digit induced
pressure alterations in the ﬁnger cuff, which were sensed by pressure transducers and transmitted to
and recorded by the EndoPAT 2000 device. EndoPAT 2000 also provides the augmentation index (AI), a
measurement of arterial stiffness via pulse-wave analysis, which was normalized to 75 bpm heart rate.
Measurements were performed by a trained professional with the participants in resting supine
conditions, in a quiet room at a constant temperature after 10 minutes of stabilization. Hyperemic
reactivity index measured by EndoPAT 2000 has been shown to predict cardiovascular disease [7].
2.7. Gene expression measurements
On the basis of their relationship with endothelial health and atherosclerosis, and the available data
of gene expression response after VOO ingestion several candidate genes were selected. Candidate
genes were AKT serine/threonine kinase 2 (AKT2), arachidonate 5-lipoxygenase (ALOX5), CD40 ligand
(CD40L), complement factor H (CFH), endothelial nitric oxide synthase 3 (eNOS), endothelial plasminogen activator inhibitor (SERPINE1), inducible nitric oxide synthase (iNOS), interferon gamma
(IFNG), interleukins (IL)1B (IL1B) and 6 (IL6), matrix metalloproteinases (MMP) 2 (MMP2) and 9 (MMP9),
mitogen-activated protein kinase 14 (MAPK14), monocyte chemoattractant protein 1 (MCP1), nuclear
factor (NF) (erythroid-derived 2)-like 2 (NEF2L2), NF-kappa B inhibitor alpha (NFKBIA), platelet-derived
growth factor subunit B (PDGFB), peroxisome proliferator-activated receptor alpha (PPARɑ), sirtuins
(SIRT) 1 (SIRT1), 2 (SIRT2), and 6 (SIRT6), transcription factor p65 (p65/RELA), tumor necrosis factor
alpha (TNF-ɑ), and vascular endothelial growth factor (VEGFA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and B-actin were used as endogenous controls to correct changes in gene
expression. Isolation of RNA from PBMC was performed with the RNeasy Mini Kit (Qiagen, Duesseldorf,
Germany). DNA complementary conversion was then carried out with the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA, USA).
Gene expression was measured, before and after interventions, by a real-time polymerase chain
reaction with a QuantStudio™ 12K Flex Real-Time PCR System (Applied Biosystems, Foster City, CA,
USA) and SYBR Green dye-based analysis. Samples were analyzed in duplicate. Results were obtained
with the Expression Suite Software v1.0.3 (Applied Biosystems, Foster City, CA, USA). Changes in gene
expression were assessed ﬁrst by calculating the relative quantiﬁcation, applying the 2eDDCT of each
sample. Thereafter, the fold change of each intervention was extracted by calculating the ratio between
values at the end and at baseline of each intervention period.
2.8. Sample size and power analyses
A total sample of 32 participants would allow at least 80% power to detect a statistically signiﬁcant
difference among groups of 0.205 units in the RHI measurement, assuming a dropout rate of 5% and
type I error of 0.005 (2-sided). The standard deviation of the measurement was assumed 0.4 [7].
2.9. Statistical analyses
Normality of continuous variables was assessed by normal probability plots and data were log
transformed when required. Intra-treatment comparisons were assessed by Student's t-test for paired
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samples. Comparisons among treatments were made by an ANOVA for repeated measures and
adjusted by age, gender, smoking, AAS medication, and baseline concentrations. In the case of lipids an
additional adjustment for LDL cholesterol values at the beginning of the clinical trial was performed. A
general lineal model was used to assess linear and quadratic trends. For the post-hoc pairwise comparison, the Tuckey test was used. Statistical analyses were performed with R (R Foundation for Statistical Computing, Vienna, Austria). version 3.0.2., and R package multcomp. Signiﬁcance was deﬁned
as p < 0.05.
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